Integrated Wealth Concepts LLC Purchases 4,831 Shares of Cencora, Inc. (NYSE:COR)

Integrated Wealth Concepts LLC raised its stake in Cencora, Inc. (NYSE:COR - Free Report) by 116.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,969 shares of the company's stock after acquiring an additional 4,831 shares during the period. Integrated Wealth Concepts LLC's holdings in Cencora were worth $2,019,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of the stock. Pacer Advisors Inc. increased its stake in Cencora by 6,855.3% in the third quarter. Pacer Advisors Inc. now owns 2,065,374 shares of the company's stock valued at $464,874,000 after acquiring an additional 2,035,679 shares during the last quarter. Legal & General Group Plc lifted its stake in Cencora by 3.7% during the second quarter. Legal & General Group Plc now owns 1,875,445 shares of the company's stock worth $422,538,000 after purchasing an additional 67,287 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Cencora by 1.2% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,552,213 shares of the company's stock valued at $349,372,000 after purchasing an additional 18,782 shares in the last quarter. Swedbank AB increased its stake in shares of Cencora by 2.3% in the 3rd quarter. Swedbank AB now owns 1,394,449 shares of the company's stock valued at $313,863,000 after purchasing an additional 31,104 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in shares of Cencora by 10.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,262,882 shares of the company's stock worth $284,544,000 after buying an additional 119,927 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors.

Cencora Trading Down 0.4 %

Shares of NYSE:COR traded down $0.90 during mid-day trading on Friday, reaching $243.41. 1,199,812 shares of the company's stock were exchanged, compared to its average volume of 1,126,541. The company has a debt-to-equity ratio of 4.84, a quick ratio of 0.53 and a current ratio of 0.88. Cencora, Inc. has a twelve month low of $195.83 and a twelve month high of $253.27. The firm has a market capitalization of $47.05 billion, a price-to-earnings ratio of 32.40, a PEG ratio of 1.65 and a beta of 0.45. The business's fifty day moving average price is $237.12 and its 200-day moving average price is $233.34.

Cencora Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, November 29th. Shareholders of record on Friday, November 15th were issued a dividend of $0.55 per share. The ex-dividend date was Friday, November 15th. This is an increase from Cencora's previous quarterly dividend of $0.51. This represents a $2.20 annualized dividend and a yield of 0.90%. Cencora's payout ratio is presently 29.29%.

Insider Buying and Selling at Cencora

In related news, Chairman Steven H. Collis sold 21,509 shares of Cencora stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $242.16, for a total value of $5,208,619.44. Following the transaction, the chairman now directly owns 306,752 shares of the company's stock, valued at $74,283,064.32. The trade was a 6.55 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In the last quarter, insiders have sold 93,018 shares of company stock worth $22,478,942. Insiders own 15.80% of the company's stock.

Wall Street Analyst Weigh In

COR has been the topic of several research analyst reports. Robert W. Baird raised their price objective on Cencora from $287.00 to $292.00 and gave the company an "outperform" rating in a research note on Thursday, November 7th. Barclays raised their price target on shares of Cencora from $263.00 to $290.00 and gave the company an "overweight" rating in a research note on Thursday, November 7th. Bank of America reiterated a "neutral" rating and set a $245.00 price objective (down from $275.00) on shares of Cencora in a research report on Wednesday, September 18th. Evercore ISI raised their target price on shares of Cencora from $250.00 to $285.00 and gave the company an "outperform" rating in a research report on Thursday, November 7th. Finally, Leerink Partners lowered their price target on shares of Cencora from $277.00 to $275.00 and set an "outperform" rating for the company in a report on Monday, October 7th. Two equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $276.80.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.